ambrisentan
Orphan DrugFDA Approved
Description
Ambrisentan is a selective endothelin type A receptor antagonist indicated for pulmonary arterial hypertension. It improves exercise capacity and delays clinical worsening in PAH patients. It has a more favorable hepatotoxicity profile compared to non-selective endothelin receptor antagonists.
Indications & Therapeutic Use
pulmonary arterial hypertension, WHO Group 1 pulmonary hypertension
Linked Diseases:
pulmonary hypertension
D006976
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
ambrisentan
| Generic Name | ambrisentan |
| Brands | 1 brand available |
| Active Ingredient | ambrisentan |
| Drug Class | pulmonary arterial hypertension |
| Manufacturer | Gilead Sciences |
| Dosage Forms | oral tablet 5mg, 10mg |
| Medical Code | C02KX02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00091559 |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes